Daniel Heng, MD, MPH, FRCPC (@DrDanielHeng), on the final analysis of the phase 3 LITESPARK-011 study: belzutifan + lenvatinib vs. cabozantinib in advanced RCC after anti–PD-(L)1 therapy. #ESMO26

Watch now: https://bit.ly/4dX3WNQ